Rapport therapeutics reports first quarter 2025 financials and provides business update

Rap-219 phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025 rap-219 phase 2a trial in patients with bipolar mania remains on track to commence in the third quarter of 2025, with topline results expected in the first half of 2027 company to host inaugural investor and analyst day on june 2, 2025, featuring presentations from management team and key opinion leader dr. jacqueline french ended the quarter with $285.4 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2026 boston and san diego, may 08, 2025 (globe newswire) -- rapport therapeutics, inc. (nasdaq: rapp), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the first quarter ending march 31, 2025, and provided a business update. “2025 represents a transformational year for rapport as we prepare to deliver our initial proof-of-concept data for rap-219 from the phase 2a trial in patients with refractory focal epilepsy and progress our pipeline-in-a-product strategy with the initiation of our bipolar mania trial.
RAPP Ratings Summary
RAPP Quant Ranking